Wall Street Zen upgrades Arcus Biosciences stock to Hold

Published on 10/05/2026 at 07:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen moved Arcus Biosciences stock to Hold. Revenue in the second quarter of 2026 reached USD 41 million versus USD 22 million expected.

RCUS, US03969F1093, Illustration mit AI erstellt.

Arcus Biosciences (US03969F1093) received a Sell-to-Hold upgrade from Wall Street Zen on October 3, 2026, as the company advances casdatifan toward several kidney cancer data readouts. The change places the analyst action alongside a second-quarter revenue result that exceeded the reported consensus estimate.

Analyst stance shifts to Hold

According to MarketBeat on October 3, 2026, Wall Street Zen raised its rating on Arcus Biosciences from Sell to Hold. The same report cited a broader Moderate Buy consensus and an average price target of USD 38.30 from 14 analysts.

The analyst backdrop is constructive but divided. MarketBeat reported that Wedbush reaffirmed an Outperform rating with a USD 43.00 target, while Goldman Sachs maintained a Buy rating with a USD 42.00 target.

Revenue beat meets pipeline spending

Arcus generated GAAP revenue of USD 41.0 million in the second quarter of 2026, compared with USD 22.0 million expected, while reporting a GAAP net loss of USD 91.0 million, or USD 0.72 per share. The revenue figure was down 74.4 percent from the second quarter of 2025, according to The Globe and Mail.

Management also guided to full-year 2026 GAAP revenue of USD 65 million to USD 75 million. Cash and marketable securities stood at USD 775 million on June 30, 2026, compared with USD 876 million at the end of the first quarter, while the company projected cash resources into at least the second half of 2028.

October data event sets the next test

Arcus plans to present new ARC-20 data for casdatifan across first-line, second-line and late-line clear cell renal cell carcinoma at an investor event on October 20, 2026, according to Yahoo Finance. The company is also targeting completion of PEAK-1 enrollment and the start of PEAK-20 by the end of 2026.

NYSE quote and valuation context

Arcus Biosciences was last at USD 24.44 on the NYSE on October 2, 2026 at 4:00 p.m. EDT. Its market capitalization was USD 3.1 billion, and its 52-week range was USD 13.61 to USD 31.74 on that date.